KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses: 2019-2025

Historic Interest Expenses for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to $22.1 million.

  • Esperion Therapeutics' Interest Expenses rose 46.21% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 35.42%. This contributed to the annual value of $59.3 million for FY2024, which is 0.47% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Interest Expenses of $22.1 million as of Q3 2025, which was up 7.64% from $20.5 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Interest Expenses registered a high of $22.1 million during Q3 2025, and its lowest value of $8.1 million during Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Interest Expenses had a median value of $15.1 million in 2023 and averaged $16.4 million.
  • In the last 5 years, Esperion Therapeutics' Interest Expenses skyrocketed by 177.07% in 2021 and then declined by 5.60% in 2024.
  • Esperion Therapeutics' Interest Expenses (Quarterly) stood at $13.4 million in 2021, then rose by 6.69% to $14.3 million in 2022, then grew by 5.08% to $15.1 million in 2023, then rose by 9.07% to $16.4 million in 2024, then spiked by 46.21% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $20.5 million for Q2 2025, and $19.4 million during Q1 2025.